Clinical Outcomes of CyberKnife Radiotherapy in Prostate Cancer Patients: Short-term, Single-Center Experience
´ëÇѺñ´¢±â°úÇÐȸÁö 2014³â 55±Ç 3È£ p.172 ~ p.177
°íµ¿ÈÆ(Koh Dong-Hoon) - Konyang University College of Medicine Department of Urology
±èÁø¹ü(Kim Jin-Bum) - Konyang University College of Medicine Department of Urology
±èÇüÁØ(Kim Hyung-Joon) - Konyang University College of Medicine Department of Urology
±èÈ«¿í(Kim Hong-Wook) - Konyang University College of Medicine Department of Urology
À念¼·(Chang Young-Seop) - Konyang University College of Medicine Department of Urology
Abstract
Purpose: In this retrospective study, we analyzed the outcomes of prostate cancer patients treated with the CyberKnife radiotherapy system (Accuray).
Materials and Methods: Between 2007 and 2010, 31 patients were treated for prostate cancer by use of the CyberKnife radiotherapy system. After excluding six patients who were lost to follow-up, data for the remaining 25 patients were analyzed. Patients were divided into the CyberKnife monotherapy group and a postexternal beam radiotherapy boost group. Clinicopathologic features and treatment outcomes were compared between the groups. The primary endpoint was biochemical recurrence-free survival period based on the Phoenix definition. Toxicities were evaluated by using the Radiation Therapy Oncology Group scoring criteria.
Results: Of 25 patients, 17 (68%) and 8 (32%) were classified in the monotherapy and boost groups, respectively. With a median follow-up of 29.3 months, most of the toxicities were grade 1 or 2 except for one patient in the boost group who experienced late grade 3 gastrointestinal toxicity. The overall biochemical recurrence rate was 20% (5/25) and the median time to biochemical recurrence was 51.9 months. None of the patients with low or intermediate risk had experienced biochemical recurrence during follow-up. Among D¡¯Amico high-risk populations, 16.7% (1/6) in the monotherapy group and 50.0% (4/8) in the boost group experienced biochemical recurrence.
Conclusions: Our data support that prostate cancer treatment by use of the CyberKnife radiotherapy system is feasible. The procedure can be a viable option for managing prostate cancer either in a monotherapy setting or as a boost after conventional radiotherapy regardless of the patient¡¯s risk stratification.
Å°¿öµå
Prostate cancer, Recurrence, Stereotactic radiosurgery, Toxicity
KMID :
0358320140550030172
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)